Deals
PE Firm Carlyle Nears Investment in GTCR-Owned Medical Company Resonetics
- PE investment could value it at $2.3 billion, including debt
- Carlyle in talks to buy about half of the health-care company
David Rubenstein, co-founder of the Carlyle Group.
Photographer: Ting Shen/BloombergThis article is for subscribers only.
Carlyle Group Inc. is in advanced discussions to invest in Resonetics, a health-care asset owned by fellow private equity firm GTCR, according to people familiar with the matter.
Carlyle is in talks to buy half of Resonetics in a deal that will value the medical-device manufacturing company at about $2.3 billion, including debt, the people said, asking not be identified because the matter is private